ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2474

Fat Mass and Resistin: Predictive Factors For Anti-TNF Therapy Response In Ankylosing Spondylitis Patients

Carla G.S. Saad1, Andressa Silva Abreu1, Ana Cristina Medeiros Ribeiro1, Julio C. B. Moraes2, Luiz A. Perandini1, Thalita Dassouki3, Rosa M. R. Pereira4, Eloisa Bonfa5 and Ana Lucia S. Pinto1, 1Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 4Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 5Rheumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adipocytokines, adipose tissue, Ankylosing spondylitis (AS), body mass and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: The adipose tissue immune properties and pharmacokinetic consequences can contribute to the pathogenesis of inflammatory conditions. The hole of fat tissue in active Ankylosing Spondylitis (AS) patients and its influence on response to anti-TNF therapy has not been widely investigated. The purpose of this study was to evaluate the fat tissue in active AS patients and the influence on clinical response to TNF blockade therapy.

Methods: 37 patients with active AS referred to receive anti-TNF therapy with high/very high disease activity according to AS Disease Activity Score (ASDAS > 2.1) and have completed 6 months of treatment were included. At baseline patients were evaluated for weight, height, body mass index (BMI), waist circumference, body composition (DXA) including total fat and trunk fat. Factors related to adipocytokines and inflammation (leptin, resistin, adiponectin, TNFα and IL-6) were also evaluated at baseline. Disease parameters and inflammatory markers [erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)] were assessed at baseline and after 6 months of treatment. Responders to anti-TNF therapy were defined according to ASDAS improvement criteria with Δ ASDAS ≥ 2.0.

Results:

Patients had a mean age of 37.0 ± 12.1 years, 75.7% were male with a mean of 9.0 ± 9.8 years of disease duration. At baseline patients had [mean (SD)]: weight 70.4(11.9)kg, BMI 26.1(4.3)kg/m2, waist circumference 89.0(10.4)cm, total fat 18.9(6.6)kg and trunk fat mass 19.5(6.7)kg. Regarding disease parameters, the mean ASDAS value was 3.2(0.9), BASFI 4.4(2.4) and BASMI 4.4(2.7). After 6 months of anti-TNF treatment 12 (32.4%) patients reached major improvement by ASDAS criteria. Comparing responders and non-responders groups we observed that the patients with good response had lower BMI (p=0.01), waist circumference (p=0.005), trunk fat mass (0.03) and higher resistin (p=0.02) serum levels and infflmmatory parameters [CRP (p=0.02) and ESR (p=0.01)]. Resistin serum levels at baseline correlated with CRP (r=0.58, p<0.01) and ESR (r=0.37, p=0.02).

Conclusion: This study provides evidence that fat mass and resistin serum levels may predict the anti-TNF response in AS patients. Further studies are necessary to elucidate the mechanism by which adipose tissue affects inflammatory condition in AS.


Disclosure:

C. G. S. Saad,

Federico Foundation,

2;

A. S. Abreu,
None;

A. C. M. Ribeiro,
None;

J. C. B. Moraes,
None;

L. A. Perandini,
None;

T. Dassouki,
None;

R. M. R. Pereira,

Federico Foundation,

2;

E. Bonfa,

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP #2009/51897-5 and 2010/10749-0), Conselho Nacional de Desenvolvimento Científico e Tecnológico (#301411/2009-3)and Federico Foundation,

2;

A. L. S. Pinto,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fat-mass-and-resistin-predictive-factors-for-anti-tnf-therapy-response-in-ankylosing-spondylitis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology